Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
0.00%
NET PROFIT MARGIN AVG 10Y
0.00%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 734 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Monopar Therapeutics Inc.
Market Cap
$524.44M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$522.99M
Net Profit Margin
-1371.51%
TTM Avg
-709.80%
3Y Avg
-108166.39%
5Y Avg
-73106.10%
Market Cap
$521.19M
Net Profit Margin
-296000.00%
TTM Avg
-345077.99%
3Y Avg
-146585.06%
5Y Avg
-98190.17%
Market Cap
$533.68M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$536.32M
Net Profit Margin
-10599.76%
TTM Avg
-44116.54%
3Y Avg
-22058.27%
5Y Avg
-14705.51%
Market Cap
$509.02M
Net Profit Margin
-56.68%
TTM Avg
-93.15%
3Y Avg
-82.60%
5Y Avg
-71.77%
Market Cap
$540.26M
Net Profit Margin
0.56%
TTM Avg
-33.88%
3Y Avg
-929.83%
5Y Avg
-984.73%
Market Cap
$540.42M
Net Profit Margin
-41.34%
TTM Avg
-365.72%
3Y Avg
-7572.59%
5Y Avg
-5048.40%
Market Cap
$503.93M
Net Profit Margin
-3566.68%
TTM Avg
-585431.82%
3Y Avg
-433391.80%
5Y Avg
-288954.46%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Monopar Therapeutics Inc. (MNPR) | $524.44M | 0.00% | 0.00% | 0.00% | 0.00% |
| Crescent Biopharma, Inc. (CBIO)vs › | $522.99M | -1371.51% | -709.80% | -108166.39% | -73106.10% |
| Altimmune, Inc. (ALT)vs › | $521.19M | -296000.00% | -345077.99% | -146585.06% | -98190.17% |
| Immix Biopharma, Inc. (IMMX)vs › | $533.68M | 0.00% | 0.00% | 0.00% | 0.00% |
| ProKidney Corp. (PROK)vs › | $536.32M | -10599.76% | -44116.54% | -22058.27% | -14705.51% |
| 908 Devices Inc. (MASS)vs › | $509.02M | -56.68% | -93.15% | -82.60% | -71.77% |
| Delcath Systems, Inc. (DCTH)vs › | $540.26M | 0.56% | -33.88% | -929.83% | -984.73% |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $540.42M | -41.34% | -365.72% | -7572.59% | -5048.40% |
| Allogene Therapeutics, Inc. (ALLO)vs › | $503.93M | -3566.68% | -585431.82% | -433391.80% | -288954.46% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $550.11M | -921.50% | -767.53% | -527.58% | -706.89% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
